Understanding Differentiated Thyroid Cancer (DTC) and Treatment Considerations for CABOMETYX® (cabozantinib)
Meeting Host
Description
Join us to hear clinical perspectives on CABOMETYX, a new option for the treatment of adult and pediatric patients 12 years of age and older with locally advanced or metastatic differentiated thyroid cancer that has progressed following prior VEGFR-targeted therapy and who are radioactive iodine-refractory or ineligible.
This program is intended for US Healthcare Professionals including: Oncologists, NPs, PAs, RNs, Pharmacists. Program is not intended for non-healthcare professionals, including guests or spouses.
When
Date: November 15, 2021
Time: 7:00 p.m. ET and 9:00 p.m. ET
Where
The Oceanaire Seafood
1100 Peachtree Street NE
Atlanta, GA 30309
Presenters
Clinical perspectives presented by:
- Marcia Brose, MD, PhD
Medical Oncologist
Thomas Jefferson University - Kirollos Hanna, PharmD, BCPS, BCOPS
Pharmacy
Mayo Clinic and M Health Fairview
This program is sponsored by Exelixis, Inc., and was developed in conjunction with Dr. Marcia Brose, and Dr. Kirollos Hanna. All participants will receive a fee for participating in this program. Program is not intended as medical advice for individual patients.
Prescribing Information
Registration
We want to hear from you! Take advantage of our live Q&A session by submitting your question in advance when you register.
Register using the link below or RSVP to:
Ann Railsback
arailsback@exelixis.com
404-245-7212
